Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Discussion session - Haematological malignancies

2563 - Bendamustine and rituximab followed by 90Y-ibritumomab tiuxetan for relapsed follicular lymphoma; a preliminary analysis of a multicenter, prospective phase II study (BRiZ2012).


21 Oct 2018


Poster Discussion session - Haematological malignancies


Cytotoxic Therapy

Tumour Site



Masatoshi Kanno


Annals of Oncology (2018) 29 (suppl_8): viii359-viii371. 10.1093/annonc/mdy286


M. Kanno1, K. Miura2, Y. Masaki3, H. Tsujimura4, M. Iino5, J. Takizawa6, Y. Maeda7, K. Yamamoto8, S. Tamura9, A. Yoshida10, H. Yagi11, I. Yoshida12, K. Kitazume13, T. Masunari14, I. Choi15, Y. Kakinoki16, T. Yoshino17, S. Nakamura18, T. Yoshida19

Author affiliations

  • 1 Oncology Center, Nara Medical University Hospital, 634-8522 - Kashihara/JP
  • 2 Hematology And Rheumatology, Nihon University School of Medicine, 173-8610 - Tokyo/JP
  • 3 Department Of Hematology And Immunology, Kanazawa Medical University, 920-0293 - Ishikawa/JP
  • 4 Division Of Hematology-oncology, Chiba Cancer Center, 260-8717 - Chiba/JP
  • 5 Department Of Medical Oncology, Yamanashi Prefectural Central Hospital, 400-8506 - Kofu/JP
  • 6 Department Of Hematology, Endocrinology And Metabolism, Niigata University Faculty of Medicine, 951-8520 - Niigata/JP
  • 7 Department Of Hematology And Oncology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 700-8558 - Okayama/JP
  • 8 Department Of Hematology,, Okayama City Hospital, 700-8557 - Okayama/JP
  • 9 Department Of Hematology, Kinan Hospital, 519-5293 - Minamimure/JP
  • 10 Department Of Hematology, Toyama Prefectural Central Hospital, 930-8550 - Toyama/JP
  • 11 Department Of Hematology, Kinki University Nara Hospital, 630-0293 - Ikoma/JP
  • 12 Hematologic Oncology, National Hospital Organization, Shikoku Cancer Center, 791-0280 - Matsuyama/JP
  • 13 Department Of Hematology, Showa General Hospital, 187-8510 - Tokyo/JP
  • 14 Department Of Hematology, Chugoku Central Hospital, 720-0001 - Fukuyama/JP
  • 15 Department Of Hematology, National Hospital Organization, Kyushu Cancer Center, 811-1395 - Fukuoka/JP
  • 16 Department Of Hematology, Asahikawa City Hospital, 070-8610 - Asahikawa/JP
  • 17 Department Of Pathology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 700-8558 - Okayama/JP
  • 18 Department Of Pathology And Biological Response, Nagoya University Graduate School of Medicine, 466-8550 - Nagoya/JP
  • 19 Member, Society of Lymphoma Treatment in Japan, 920-0953 - Kanazawa/JP


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 2563


Bendamustine and rituximab (BR) is a standard treatment for relapsed or newly diagnosed follicular lymphoma (FL). Despite, the role of 90Y-ibritumomab tiuxetan (90YIT) has been evaluated as consolidative therapy in FL responding to frontline chemotherapy, this consecutive therapy has not been well evaluated in relapsed setting.


This is a planned preliminary analysis of a prospective phase II study to clarify the efficacy and safety of BR followed by consolidative 90YIT in relapsed FL patients. Inclusion criteria is defined as following conditions: relapsed patients with biopsy proven FL (Grade 1/2 or 3a); limitation of one or two previous regimens; age of 20 - 74 years; performance status of 0 - 2; having measurable lesion(s); no severe organ dysfunction; 3 months or longer life expectancy; and written informed consent. BR consisted of intravenous rituximab (375 mg/m2, day 1) and bendamustine (90 mg/m2, day 2 and 3), repeated every 4 weeks up to 4 cycles. Patients who achieved complete response (CR) or partial response received 14.8 MBq/kg of 90YIT continuously. In this analysis, overall response (OR) rates and CR rates after 4 cycles of BR and 90YIT, and toxicities were evaluated.


Between February 2013 and November 2015, a total of 30 patients were registered. Seven patients were excluded from this analysis because of pathological diagnostic mismatch (n = 3), unmet criteria (n = 2), comorbidity with other active cancer (n = 1), and reviewed data incompletion (n = 1). Twenty-three patients with a median 60 years (range 47–74) were evaluable. Fourteen, 7, and 2 patients were categorized into low, intermediate, and high risk in the FLIPI 2, respectively. OR rates and CR rates were 91% (n = 22) and 74% (n = 18) after BR, and 88% (n = 21) and 83% (n = 20) after 90YIT, respectively. Hematological toxicities commonly observed, however these were generally tolerable. Grade ≥3 non-hematological toxicities were rare and there was no treatment-related death.


Combination with BR followed by 90YIT was safe and effective for selected patients with relapsed FL. The further investigation of Long-term effect has been on going.

Clinical trial identification

UMIN000008793, release date: 03. September 2012.

Legal entity responsible for the study

Society of Lymphoma Treatment in Japan.


NP-ACRO (Advanced Clinical research Organization).

Editorial Acknowledgement


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.